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Abstract
Apolipoprotein L1 gene (APOL1) G1 and G2 coding variants are strongly associated with chronic 
kidney disease (CKD) in African Americans. Here APOL1 association was tested with baseline 
estimated glomerular filtration rate (eGFR), urine albumin:creatinine ratio (UACR), and prevalent 
cardiovascular disease (CVD) in 2,571 African Americans from the Systolic Blood Pressure 
Intervention Trial (SPRINT), a trial assessing effects of systolic blood pressure reduction on renal 
and CVD outcomes. Logistic regression models that adjusted for potentially important 
confounders tested for association between APOL1 risk variants and baseline clinical CVD 
(myocardial infarction, coronary or carotid artery revascularization) and CKD (eGFR under 60 
ml/min/1.73m2 and/or UACR over 30 mg/g). African American SPRINT participants were 45.3% 
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female with mean (median) age of 64.3 (63) years, mean arterial pressure 100.7 (100) mmHg, 
eGFR 76.3 (77.1) ml/min/1.73m2, UACR 49.9 (9.2) mg/g, and 8.2% had clinical CVD. APOL1 
(recessive inheritance) was positively associated with CKD (odds ratio 1.37, 95% confidence 
interval 1.08–1.73) and log UACR estimated slope [β] 0.33) and negatively associated with eGFR 
(β −3.58), all significant. APOL1 risk variants were not significantly associated with prevalent 
CVD (1.02, 0.82–1.27). Thus, SPRINT data show that APOL1 risk variants are associated with 
mild CKD but not prevalent CVD in African American with a UACR under 1000 mg/g.
Keywords
African Americans; albuminuria; APOL1; cardiovascular disease; chronic kidney disease; 
SPRINT
Introduction
There has been significant progress in the delineation of the spectrum of non-diabetic 
chronic kidney disease (CKD) in African Americans (AAs) that are associated with the 
apolipoprotein L1 gene (APOL1) G1 and G2 coding variants. Patients with APOL1-
associated primary glomerulosclerosis often have proteinuria, secondary hypertension, and 
focal segmental glomerulosclerosis (FSGS), HIV-associated nephropathy (HIVAN; FSGS, 
collapsing variant), focal global glomerulosclerosis accompanied by interstitial and vascular 
changes (often labeled “hypertension-attributed” nephropathy), sickle cell nephropathy, or 
severe lupus nephritis on kidney biopsy.1–6 Patients inheriting two APOL1 risk variants have 
high rates of progression to end-stage kidney disease (ESKD), explaining a large fraction of 
the differential risk of ESKD in AAs.6–8 However, the specific disease mechanisms remain 
unclear. Modifying genetic (APOL1 by second gene) and environmental factors (APOL1 by 
environmental exposure) are likely present and may account for the variable glomerular 
histologic lesions.3;9–12Weaker APOL1 association is observed with albuminuria and 
reduced kidney function in population-based studies of AAs.13–15
Recent results from the Jackson Heart Study (JHS) and Women’s Health Initiative (WHI) 
reported an association between APOL1 nephropathy variants and incident cardiovascular 
disease (CVD).16 This finding warrants additional consideration, since the African 
American Study of Kidney Disease and Hypertension (AASK) did not detect a significant 
relationship between APOL1 and participant survival.8 AASK extended APOL1 association 
to AAs with putative hypertension-attributed nephropathy and urine protein:creatinine ratios 
(UPCR) less than 2,500 mg/g,7 but did not appear to support APOL1 association with 
CVD.8 AASK also demonstrated that although aggressive blood pressure control slowed 
nephropathy progression in participants who had proteinuria exceeding 300 mg/day, the 
overall response to renin-angiotensin system (RAS) blockade was poor and nearly 60% of 
AASK participants met a primary study end-point (mainly nephropathy progression, not 
death) within 10 years.17 APOL1 was significantly associated with CKD in AASK cases and 
only APOL1 genotype predicted nephropathy progression, blood pressure treatment arm and 
medication class did not.7 Therefore, AASK suggested that APOL1 is primarily involved in 
progression of non-diabetic nephropathy, without independent effects on CVD. As such, it is 
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unclear why JHS and WHI results differed from those in AASK. Approximately one quarter 
of JHS and WHI participants had diabetes mellitus, a known CVD risk factor, and their 
CVD definition differed from those employed in the National Institutes of Health (NIH)-
sponsored AASK and Systolic Blood Pressure Intervention Trial (SPRINT).16 AASK also 
excluded subjects with diabetes mellitus, congestive heart failure (CHF), or heart block 
greater than first degree.18 Thus, analysis of other large cohorts is important to define 
potential relationships between APOL1 and CVD.
The present analyses assessed APOL1 G1 and G2 risk variant association with prevalent 
CVD and baseline CKD, eGFR, and albuminuria in AAs at high risk for CVD from 
SPRINT.19 SPRINT enrolled large numbers of non-diabetic individuals with hypertension; 
participants were enriched for CVD and associated risk factors, the elderly, and those with 
nephropathy having low levels of albuminuria.
Results
Among all 2,802 AAs enrolled in SPRINT, 2,571 (91.8%) consented to participate in 
genetic research studies and had baseline clinical and APOL1 G1 and G2 genotype data that 
passed quality control analyses. In the multivariate analysis, 342 of 2,802 participants were 
excluded due to failure to provide consent for genetic analyses, lack of DNA, or missing 
covariates. Compared with those in the multivariate analysis, no significant differences were 
observed for excluded participants regarding age, sex, body mass index (BMI), number of 
BP medications, or CVD events; although higher mean ± standard deviation (SD) (median) 
eGFR 79.0 ± 21.0 (78.6) ml/min/1.73 m2 (p=0.03) and a trend toward lower urine 
albumin:creatinine ratio (UACR) 25.5±56.9 (8.1) mg/g (p=0.0501) were present 
(Supplementary Table 1 contains characteristics of participants included and excluded from 
the multivariate analysis).
Individuals in this analysis were 45.3% female with mean±SD (median) age 64.3±9.3 (63) 
years, mean arterial pressure 100.7±12.2 (100) mmHg, CKD-Epidemiology (EPI) estimated 
glomerular filtration rate (eGFR) 76.3±22.9 (77.1) ml/min/1.73m2, UACR 49.9±188.6 (9.2) 
mg/g and 16.2% had CVD defined by the SPRINT Manual Of Operations (MOO; see 
Methods), while 8.2% had clinical CVD defined as prior coronary or carotid artery 
revascularization (surgical or percutaneous) or myocardial infarction (MI). Table 1 
summarizes the demographic and clinical differences between those individuals with zero or 
one copies versus two copies of the APOL1 G1/G2 risk alleles. Briefly, those with two risk 
variants were one year younger, but otherwise these two groups had similar proportions of 
women and similar BMI, tobacco use, and fasting glucose levels. Individuals with two 
copies of the APOL1 risk variants had higher African ancestry (82% vs. 78%, p=4.2×10−9) 
and albuminuria (p=3.8×10−6) and more kidney disease (serum creatinine concentration 
p=0.0091; eGFR p=0.0249; CKD prevalence p=0.0129), even after adjusting for multiple 
comparisons.20 In contrast to CKD, Table 1 reveals the general absence of APOL1 
association with baseline measures of CVD, whether defined as in the SPRINT MOO or 
clinical CVD (MI, coronary or carotid artery revascularization).
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In order to account for the potentially confounding effects of age, gender, RAS blockade and 
African ancestral proportion on risk for kidney disease, multiple regression models that 
adjusted for these a priori factors as covariates were computed (Table 2). In the multiple 
logistic model, individuals with two copies of the G1/G2 risk variants had a higher 
prevalence of CKD (odds ratio (OR) = 1.37, p=0.0095), had lower eGFR (slope (β̂) = −3.57, 
p=0.0029), and higher levels of albuminuria (log(UACR); slope (β̂) = 0.33, p=7.67×10−6), 
compared to those with zero or one risk variants. Comparable effect sizes were observed if 
the sample was restricted to >0.40 and >0.80 African ancestry (data not shown).
A similar multiple logistic regression approach was computed to test for an association 
between APOL1 risk variants and clinical CVD (Table 3). Specifically, a logistic regression 
model was computed with prevalent CVD as the response and adjusting for an a priori list 
of CVD risk factors (i.e., age, gender, BMI, number of blood pressure medications, statin 
use, eGFR, ACR, and smoking) and African ancestral proportion as covariates. As with the 
univariate analysis in Table 1, the adjusted analyses in Table 3 show no evidence of an 
association between the number of APOL1 risk variants (additive genetic model) and 
clinical CVD (p=0.86, OR 1.02, 95% confidence interval [CI] 0.82–1.27). Adjusting for the 
same list of covariates but testing for an APOL1 association under a recessive model yielded 
comparable results (p=0.54). The number of blood pressure medications, use of statins and 
smoking were significantly associated with clinical CVD. Given the lack of association with 
APOL1, it is important to consider whether the study had sufficient power to detect the 
effect size (OR=2.0) reported in the JHS/WHI study.16 Thus, a power analysis was 
computed to estimate the power to detect the APOL1 G1/G2 variant association with CVD 
assuming an additive genetic model, G1/G2 risk allele frequency of 0.36, a clinical CVD 
rate of 8.5% and a type 1 error rate of α=0.05. The 2,571 individuals analyzed have ~0.80 
power for an OR=1.26, ~0.90 power for OR=1.31 and >0.99 power for OR=1.43. A similar 
analysis assuming a recessive model yields power estimates of 0.80 for OR=1.53, 0.90 for 
OR=1.63 and >0.99 for OR=1.87. Thus, SPRINT has excellent power to detect the effect 
sizes of OR=2.0 reported in the JHS/WHI study16 and the difference in results are likely 
attributable to ascertainment (e.g., diabetes mellitus) and other study-specific design features 
and not sampling variation.
Discussion
Impressive genetic association exists between the G1 and G2 coding variants in APOL1 and 
a spectrum of non-diabetic, often proteinuric nephropathies in populations with recent 
African ancestry.21–23 The extent of this association has been less clear in individuals with 
mild CKD and lower levels of proteinuria as in SPRINT, as well as for CVD. The present 
analyses demonstrate significant association between APOL1 and mild CKD in hypertensive 
AAs with a UACR below 1,000 mg/g, but not with CVD. As such, it is inconclusive 
whether APOL1 independently associates with CVD beyond its known effect on renal blood 
vessels (glomeruli and the renal microvasculature). APOL1 protein is detectable in the 
media of medium-sized arteries and arterioles in subjects with kidney disease (FSGS or 
HIVAN).24 Therefore, APOL1 could potentially play roles in susceptibility to large vessel 
disease including MI and stroke. However, CKD uniformly associates with increasing rates 
of CVD and CVD-associated mortality.
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Because of the close relationship between CKD and CVD, it may be difficult to assess the 
direct effect of APOL1 on CVD, independent of CKD and albuminuria, on the basis of 
statistical adjustment. Ito and colleagues reported an excess of adjudicated and verified CVD 
events among APOL1 two risk variant carriers in the JHS and WHI, including after 
adjustment for CKD.16 However, they also noted that JHS participants with two APOL1 risk 
variants had paradoxically lower levels of coronary artery calcified atherosclerotic plaque 
(CAC) than did those with less than two risk variants. CAC is a powerful predictor of 
subsequent risk for MI, stroke, CVD, and mortality.25;26 The protective effect of APOL1 
risk variants on CAC might not be expected if APOL1 risk variants underlie CVD. To 
explain this finding, the authors suggested that novel CVD pathways may be present.16
The mean ± SD (median) UACR among SPRINT AAs included in these analyses were 
49.9±188.6 (9.2) mg/g; in those with two APOL1 risk variants it was 65.9±175.2 (12.1) 
mg/g. Although the relationships between albuminuria and proteinuria are not entirely 
consistent across different etiologies of CKD, the levels of proteinuria in SPRINT appear to 
be lower than those in AAs enrolled in AASK and CRIC. APOL1 was associated with 
progression of CKD in both AASK and CRIC, and with presence of baseline CKD in 
AASK.7;8 AASK enrolled hypertensive non-diabetic AAs with a UPCR <2,500 mg/g. The 
median (95% CI) UPCR in AASK participants was 74.2 (27.4–307.4) mg/g; among those 
with two APOL1 risk variants UPCR was 203.0 (43.2–723.4) mg/g. AASK included the 
following cardiovascular (CV) end-points, adjudicated CV death and hospitalization for MI, 
stroke, CHF, revascularization procedures, and other hospitalized CV events.18 In AA CRIC 
participants lacking diabetes, the mean ± SD (median) 24 hour urine protein excretion was 
600±1,300 (100) mg; among those with two APOL1 risk variants the 24 hour urine protein 
excretion was 900±1,600 (400) mg. Proteinuria impacts CKD progression independently 
from APOL1;8 however, SPRINT demonstrates that CKD in non-diabetic hypertensive AAs 
without heavy proteinuria is significantly related to APOL1. The strength of the SPRINT 
APOL1 association with CKD likely resides between those reported in population-based 
samples of AAs (and family members of AAs with non-diabetic forms of ESKD) where 
participants were not enrolled based on presence of hypertension or CKD, and those in 
samples with ESKD, AASK, and CRIC where participants were highly enriched for 
advanced CKD or ESKD. 7;8;13–15 Approximately 14% of AAs in SPRINT possess two 
APOL1 G1 or G2 risk variants, similar to the 12–13% frequencies observed in the general 
AA population.1 This likely reflects that SPRINT recruited hypertensive AAs without 
advanced CKD; only 33% had reduced eGFR (the majority mildly reduced) and/or low level 
proteinuria.
In SPRINT, we note the lack of APOL1 association with baseline (prevalent) CVD including 
MI and coronary or carotid artery revascularization in a high-risk non-diabetic sample. 
Absence of APOL1 association with CVD in SPRINT was observed despite significant 
association between APOL1 and kidney disease in a population recruited to be at heightened 
risk for CVD. It is unlikely that this report contained a biased SPRINT sample; 91.8% 
(2,571/2,802) of all randomized AAs provided DNA and were included in the study. If 
APOL1 is associated with death from CVD, the baseline SPRINT sample might not reflect 
this and longer term follow-up would be required to demonstrate an association with CVD. 
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Further, statistical power does not explain the lack of an association. The lack of APOL1 
association with CVD is supported by AASK.8 The AASK primary outcome included a 
composite of progression of CKD to ESKD, doubling of serum creatinine concentration, or 
death.27 Despite strong APOL1 association with the primary AASK composite outcome, 
significant association between APOL1 and death was not detected after nearly ten year 
follow-up.8 The vast majority of AASK participants reaching a primary outcome had a renal 
event.28 We add that there were only 59 CVD deaths in AASK after ten years and 
approximately 70% of participants underwent APOL1 genotyping. Hence, AASK was not 
focused on CVD deaths and could have been underpowered.
Many differences exist between the JHS, WHI, AASK, and SPRINT studies and these likely 
contributed to differences in observed effect of APOL1 nephropathy variants on risk for 
CVD. SPRINT enrolled hypertensive participants with high risk for subsequent CVD events, 
but excluded participants with stroke, diabetes, proteinuria >1 gram per day, eGFR <20 
ml/min/1.73m2, moderate to severe CHF, or non-adherence. Although AASK and SPRINT 
enrolled only hypertensive individuals without diabetes, approximately 25% of JHS and 
WHI participants had diabetes and those who had prior strokes were included. As such, it is 
conceivable that presence of diabetes underlies the disparate association results between 
JHS/WHI and AASK/SPRINT. In the report by Ito et al. there appears to be a positive 
correlation between diabetes and the number of APOL1 risk alleles (JHS: p-value=0.0012; 
WHI: p-value=0.0428); these p-values are based on the frequencies and counts in their Table 
1.16 In addition, the events included in the CVD category in WHI included cerebrovascular 
disease and stroke and in JHS included stroke. Thus, given the strong relationship between 
diabetes and CVD, it would be interesting to examine the relationship between APOL1 and 
CVD in the JHS and WHI, stratified by diabetes status. Finally, AASK, JHS, and WHI also 
benefitted from longitudinal follow-up and adjudicated event reporting. Longer-term follow-
up in SPRINT will be necessary to firmly determine whether potential associations exist 
between APOL1 and adjudicated MI, stroke, CHF, coronary revascularization, PVD, and 
death, as well as determine effects of blood pressure treatment on these CVD outcomes 
based on genotype.
We conclude that APOL1 G1 and G2 coding variants are significantly associated with the 
presence of CKD, degree of albuminuria, and eGFR in AA SPRINT participants. In contrast 
to prior NIH cohort studies enrolling AAs with non-diabetic forms of advanced 
nephropathy, SPRINT participants have far lower levels of albuminuria and higher eGFRs at 
baseline. Baseline SPRINT results suggest that APOL1 association may be limited to (or 
stronger with) nephropathy, with no effect seen for prevalent CVD. Long term follow-up 
will be required to determine whether APOL1 associates with risk of incident CVD in 
SPRINT. Several studies reveal that AAs who possess two APOL1 risk variants are at higher 
risk for progression of nephropathy, this despite RAS blockade and intensive blood pressure 
reduction. Although treating hypertension and attempting to reduce proteinuria remain 
paramount, it is imperative that we identify the pathogenetic mechanisms involved in 
APOL1-associated nephropathy. This will lead to novel treatments for this refractory 
spectrum of kidney diseases that are limited to those with recent African ancestry.
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Materials and Methods
Study Participants
SPRINT is a two-armed NIH-sponsored randomized multicenter trial designed to test 
whether a treatment protocol aimed at reducing systolic blood pressure beyond current 
treatment guidelines will reduce CVD and renal outcomes in a high-risk multi-ethnic sample 
with hypertension. SPRINT is enriched for the elderly, ethnic minorities, subjects with 
CKD, and/or at high risk for CVD based on presence of hypertension in those aged 50 years 
or older, plus at least one of the following: clinical or subclinical CVD (excluding stroke), 
CKD, Framingham risk score for ten year CVD event ≥15%, or age greater than 75 years. 
Subjects with CKD had a baseline UACR less than 1,000 mg/g and CKD-EPI equation 
computed (serum creatinine-based) estimated glomerular filtration rate (eGFR) between 20 
and 59 ml/min/1.73m2.29 Inclusion and exclusion criteria have been reported.19
All self-described AAs of non-Hispanic ethnicity in SPRINT who provided DNA and 
consented to molecular genetics analyses were evaluated in this report. Herein, CKD was 
defined as an individual having a UACR >30 mg/g and/or CKD-EPI eGFR <60 ml/min/
1.73m2. We focused on a clinical CVD definition that was limited to prior coronary or 
carotid artery revascularization or MI. In addition, we report prevalent CVD events as 
defined in the SPRINT MOO recorded at baseline; including myocardial infarction; acute 
coronary syndrome with or without resting electrocardiographic (ECG) changes, ECG 
changes on graded exercise test, or positive cardiac imaging study; coronary 
revascularization (coronary artery bypass grafting or percutaneous coronary intervention); 
carotid endarterectomy or carotid stenting; peripheral arterial disease with revascularization; 
50% stenosis of a coronary, carotid, or lower extremity artery; abdominal aortic aneurysm 
≥5 cm with or without repair; coronary artery calcium score ≥400 Agatston units; ankle-
brachial index ≤0.90; and left ventricular hypertrophy by computer ECG reading, 
echocardiogram report, or other cardiac imaging procedure. The frequencies of CVD using 
both definitions are included in Table 1. All participants were evaluated for CVD history at 
the screening visit during an interview by clinic staff. The evaluation of inclusion and 
exclusion criteria became part of the participant’s chart as source documentation, but this 
documentation is not part of the study database. Documentation included medical records, 
test and procedure reports, hospital discharge summaries, and ECG tracings. No tests or 
procedures were performed by the study for the purpose of determining eligibility related to 
CVD history. Participants with stroke, diabetes, proteinuria >1 gram/day, eGFR <20 
ml/min/1.73m2, symptomatic CHF or ejection fraction <35%, or with non-adherence were 
excluded. Incident strokes are being captured prospectively during the trial. CVD events 
recorded at enrollment included history of MI, angina, CHF, TIA, revascularization of 
coronary or carotid arteries, and PVD.
Genotyping
Two single nucleotide polymorphisms (SNPs) in the APOL1 G1 nephropathy risk allele 
(rs73885319; rs60910145) and an insertion/deletion polymorphism for the G2 risk allele 
(rs71785313) were genotyped in all subjects using a custom assay designed in the Wake 
Forest School of Medicine Center of Genomics and Personalized Medicine Research on the 
Langefeld et al. Page 7
Kidney Int. Author manuscript; available in PMC 2015 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Sequenom platform (San Diego, California). The G1 and G2 genotype calls were visually 
inspected for quality control. In addition, 106 biallelic ancestry informative markers were 
genotyped to provide African ancestry proportion estimates. The maximum likelihood 
approach of Tang et al. as coded in the package FRAPPE (frequentist estimation of 
individual ancestry proportion) was used to obtain the proportion of African and European 
ancestry for each individual.30 Genotype data at these markers were obtained from 44 
HapMap Yoruba individuals (YRI) and 39 European American controls as anchors and 
provided starting values for the Expectation-Maximization algorithm used in FRAPPE.
Statistical Analyses
Quality control analyses were completed on both the clinical and genotype data. Clinical 
data were examined for implausible and aberrant observations, outliers that might have 
undue influence on the analyses and consistency across related variables. The APOL1 SNPs 
were examined for the quality of the genotyping calls, departures from Hardy-Weinberg 
Equilibrium expectations and differential missingness by CKD versus controls. To test for 
differences between the clinical and demographic characteristics and the APOL1 risk 
variants, individuals with two copies of the G1/G2 risk variants (recessive model as in prior 
reports)1–6 were contrasted with those with zero or one copies (i.e., recessive model) using a 
generalized linear models (i.e., logistic regression for CKD and CVD and linear regression 
for UACR and eGFR). Model assumptions of conditional normality, homogeneity of 
variance and overly influential observations were examined, resulting in UACR being 
modeled using a natural logarithm transformation; CKD-EPI eGFR did not require a 
transformation in these data. To account for the three hypotheses tested, the sharper 
Bonferroni multiple comparisons adjustment was used.20
To account for the potential confounding effects of the demographic and clinical 
characteristics on the associations between APOL1 G1/G2 risk variants and CVD and CKD-
related traits, multiple linear or logistic regression analyses were computed. Associations for 
CKD (logistic regression), log(UACR) (linear regression) and CKD-EPI eGFR (linear 
regression) adjusted for age, gender, African ancestry proportion, and RAS blockade (either 
ACEi or angiotensin receptor blockers) as covariates. Similarly, the association of APOL1 
G1/G2 risk variants and CVD (logistic regression) adjusted for age, gender, BMI number of 
blood pressure medications, statin use, eGFR, ACR, smoking and African ancestry 
proportion. Here, the APOL1 G1/G2 risk was modeled under an additive genetic model (0, 
1, or 2 copies of the risk alleles) and a recessive genetic model (0 or 1 versus 2 copies of risk 
alleles). ORs and 95% CI are computed for a change of one unit on the predictor variable 
scale (e.g., increase of one in the number of APOL1 risk variants, increase of one on the 
BMI scale, increase of one in the number of blood pressure medications). A power analysis 
was computed for CVD and APOL1 risk variants using Quanto.31
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Baseline demographic and laboratory data in African American SPRINT participants*
Variable APOL1 2 risk variants (N=361) APOL1 0/1 risk variants (N=2210) P-value (2 vs. 0/1 risk 
variants)
Sex, % Female 46.8 45.1 0.5472
Age, years 63.4±9.0 (61) 64.4±9.0 (63) 0.0325
Body Mass Index, kg/m2 31.5±6.7 (30.4) 30.8±6.3 (30.1) 0.1107
Number of BP meds 2.06±1.08 (2) 1.95±1.04 (2) 0.0801
% African ancestry 0.82±0.09 (0.84) 0.78±0.12 (0.80) 4.23×10−9
Systolic BP, mmHg 139.4±15.8 (137) 139.8±16.4 (138) 0.6035
Diastolic BP, mmHg 82.3±12.6 (82) 81.1±12.4 (81) 0.0816
UACR, mg/g 65.9±175.2 (12.1) 47.2±190.6 (8.7) 3.75×10−6
% UACR >30 mg/g 26.3 19.0 0.0013
% UACR >300 mg/g 6.7 3.0 0.0004
Serum creatinine, mg/dL 1.21±0.50 (1.08) 1.13±0.37 (1.05) 0.0091
Chronic Kidney Disease+,% 41.0 34.3 0.0129
eGFR, ml/min/1.73m2 73.4±24.7 (74.9) 76.8±22.6 (77.4) 0.0249
% eGFR <60 ml/min/1.73m2 28.2 23.7 0.0652
ACEi/ARB use,% 56.2 52.1 0.1474
% Tobacco 0.1801
 Current 24.1 22.7
 Former 28.5 33.2
 Never 47.7 44.1
Pack years in smokers 7.8±12.7 (0.9) 9.1±15.4 (1.5) 0.1718
CVD, % (defined in Methods) 16.6 16.2 0.8576
Clinical CVD, % (defined below) 8.9 8.1 0.6230
Angina, % 7.0 7.9 0.5615
Carotid Endarterectomy,% 3.1 1.7 0.0872
Congestive Heart Failure,% 3.9 4.4 0.6828
Coronary Revascularization,% 4.7 4.0 0.5175
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Variable APOL1 2 risk variants (N=361) APOL1 0/1 risk variants (N=2210) P-value (2 vs. 0/1 risk 
variants)
Myocardial Infarction, % 6.4 5.3 0.4247
Peripheral Vascular Disease,% 6.1 4.8 0.2722
Transient Ischemic Attack,% 0.2 2.4 0.2464
Statin use,% 34.1 33.7 0.8928
Fasting glucose, mg/dL 96.8±13.9 (95) 97.9±16.0 (96) 0.1237
*
Mean + standard (median);
+CKD defined as UACR >30 mg/g and/or eGFR <60 ml/min/1,73m2;
BP – blood pressure; UACR – urine albumin:creatinine ratio; eGFR – CKD-EPI equation estimated glomerular filtration rate; ACEi/ARB – 
angiotensin converting enzyme inhibitor/angiotensin receptor blocker; CVD – cardiovascular disease; Clinical CVD includes myocardial infarction 
and coronary or carotid artery revascularization
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Table 2
Differences in risk for chronic kidney disease and related parameters as a function of the number of APOL1 
G1/G2 risk variants (0/1 versus 2).
CKD modeled using logistic regression Odds Ratio 95% Confidence Interval P-value
Intercept - - -
Age (five year change) 1.32 1.26–1.38 <0.0001
Female 1.27 1.08–1.51 0.0049
ACEi/ARB 1.23 1.04–1.45 0.0162
Admixture 2.63 1.30–5.33 0.0075
APOL1 G1/G2 compound risk 1.37 1.08–1.73 0.0095
eGFR modeled using linear regression
β̂ se(β) P-value
Intercept 153.90 4.23 <0.0001
Age −0.97 0.05 <0.0001
Female −2.28 0.83 0.0064
ACEi/ARB −4.94 0.83 <0.0001
Admixture −14.11 3.45 <0.0001
APOL1 G1/G2 compound risk −3.57 1.20 0.0029
Log(UACR) modeled using linear regression
β̂ se(β) P-value
Intercept 1.16 0.26 0.2621
Age 0.016 0.003 <0.0001
Female 0.066 0.052 0.2027
ACEi/ARB 0.058 0.051 0.2540
Admixture 0.33 0.21 0.1171
APOL1 G1/G2 compound risk 0.33 0.07 7.67×10−6
ACEi/ARB – angiotensin converting enzyme inhibitor/angiotensin receptor blocker
eGFR – estimated glomerular filtration rate based on CKD-EPI equation;
UACR – urine albumin:creatinine ratio
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